Literature DB >> 17689908

MR imaging in local staging of prostate cancer.

Jurgen J Fütterer1.   

Abstract

Clinical staging to differentiate between localized and advanced disease stage appear to be unreliable. Curative therapy can only be performed in patients with localized prostate cancer. Accurate staging is therefore especially important for proper disease management. Since 1984 magnetic resonance (MR) imaging has been applied for this purpose. However, the role of MR imaging of the prostate is debated extensively in the literature. Initially MR imaging was performed using a conventional body coil with subsequent limited anatomical detail due to insufficient spatial resolution. With the introduction of new MR sequences, new coils and other technical developments numerous studies have attempted to improve local staging. The diagnostic capability of MR imaging in preoperative staging of prostate cancer is currently being established. In this review the role of MR imaging in staging prostate cancer is discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17689908     DOI: 10.1016/j.ejrad.2007.06.029

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  18 in total

Review 1.  Is it time to consider a role for MRI before prostate biopsy?

Authors:  Hashim U Ahmed; Alex Kirkham; Manit Arya; Rowland Illing; Alex Freeman; Clare Allen; Mark Emberton
Journal:  Nat Rev Clin Oncol       Date:  2009-04       Impact factor: 66.675

2.  Open MR-guided high-dose-rate (HDR) prostate brachytherapy: feasibility and initial experiences open MR-guided high-dose-rate (HDR) prostate brachytherapy.

Authors:  Ferenc Lakosi; Gergely Antal; Csaba Vandulek; Arpad Kovacs; Gabor L Toller; Istvan Rakasz; Gabor Bajzik; Janaki Hadjiev; Peter Bogner; Imre Repa
Journal:  Pathol Oncol Res       Date:  2011-01-11       Impact factor: 3.201

3.  Magnetic resonance imaging for prostate cancer clinical application.

Authors:  Bing Li; Yong Du; Hanfeng Yang; Yayong Huang; Jun Meng; Dongmei Xiao
Journal:  Chin J Cancer Res       Date:  2013-04       Impact factor: 5.087

Review 4.  Functional magnetic resonance imaging and molecular pathology at the crossroad of the management of early prostate cancer.

Authors:  Raphaele Renard-Penna; Geraldine Cancel-Tassin; Eva Comperat; Morgan Roupret; Pierre Mozer; Olivier Cussenot
Journal:  World J Urol       Date:  2015-05-06       Impact factor: 4.226

5.  Role of surgery in high-risk localized prostate cancer.

Authors:  N Lawrentschuk; G Trottier; C Kuk; A R Zlotta
Journal:  Curr Oncol       Date:  2010-09       Impact factor: 3.677

6.  Three-dimensional elastic image registration based on strain energy minimization: application to prostate magnetic resonance imaging.

Authors:  Bao Zhang; Dwayne D Arola; Steve Roys; Rao P Gullapalli
Journal:  J Digit Imaging       Date:  2011-08       Impact factor: 4.056

7.  The predictability of T3 disease in staging MRI following prostate biopsy decreases in patients with high initial PSA and Gleason score.

Authors:  Young Hwii Ko; Deuk Jae Sung; Sung Gu Kang; Seok Ho Kang; Jeong Gu Lee; Je Jong Kim; Jun Cheon
Journal:  Asian J Androl       Date:  2011-03-07       Impact factor: 3.285

8.  Role of multiparametric magnetic resonance imaging in the diagnosis of prostate cancer.

Authors:  Soroush Rais-Bahrami; Baris Turkbey; Kinzya B Grant; Peter A Pinto; Peter L Choyke
Journal:  Curr Urol Rep       Date:  2014-03       Impact factor: 3.092

9.  Can we predict real T3 stage prostate cancer in patients with clinical T3 (cT3) disease before radical prostatectomy?

Authors:  Hye Won Lee; Seong Il Seo; Seong Soo Jeon; Hyun Moo Lee; Han Yong Choi
Journal:  Yonsei Med J       Date:  2010-09       Impact factor: 2.759

10.  Technical feasibility of transperineal MR-guided prostate interventions in a low-field open MRI unit: canine study.

Authors:  Ferenc Lakosi; Gergely Antal; Csaba Vandulek; Arpad Kovacs; Rita Garamvolgyi; Ors Petnehazy; Gabor Bajzik; Janaki Hadjiev; Imre Repa; Peter Bogner
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.